Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure
Danay Cibrián(Instituto de Salud Carlos III), Raymond J. Playford(University of West London), Robert A. Goodlad(The Honourable Society of Lincoln's Inn), Freya Freyre(Centro de Ingeniería Genética y Biotecnología), Joseph J. Boyle(Imperial College London), José Suárez Alba(Centro de Ingeniería Genética y Biotecnología), Gerardo Guillén(Hunan City University), Tania Marchbank(Queen Mary University of London), M. Kim(Hammersmith Hospital), Subrata Ghosh(University College Cork), Diana García del Barco(Centro de Ingeniería Genética y Biotecnología), Pedro López‐Saura(United States Nuclear Regulatory Commission), Jorge Berlanga(Centro de Ingeniería Genética y Biotecnología), Olga Sonia León(Centro de Ingeniería Genética y Biotecnología), Hussam Ajamieh(University of Havana)
Cited by 23
Related Papers
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Cells of the adult human heart
|Nature|2020|1.8k
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
|New England Journal of Medicine|2012|1.1k
CD69: from activation marker to metabolic gatekeeper
|European Journal of Immunology|2017|935
Newly identified genetic risk variants for celiac disease related to the immune response
|Nature Genetics|2008|690